Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone Extension in Alzheimer's Disease
NCT00381238Phase 2Completed
- Sponsor
- GSK
- Start
- Jun 2006
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of rosiglitazone in Alzheimer's disease (AD), sponsored by GSK. Primary endpoint: Number of Participants With Adverse Events at 50 weeks. Started Jun 2006; status: completed.
02
Drugs
rosiglitazone
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00381238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00381238.